A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patients With Advanced Solid Tumors

A Phase I, First in Human, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301, a Lipid Nanoparticle Suspension of Akt-1 Antisense Oligonucleotide, in Patients With Advanced Solid Tumors

The purpose of this study is to learn about the effects of a study medicine, WGI-0301 to find the best dose for treating solid tumors, and to see how safe and tolerable the study drug is for patients with solid tumors.

The study is also done to learn how the study drug is taken up by your body; this is called Pharmacokinetic (PK) studies and how the study drug affects the body; this is called Pharmacodynamics (PD)

Study Overview

• Status: Recruiting
• Conditions: Advanced Solid Tumors
• Intervention / Treatment: Drug: WGI-0301

• Study Type: Interventional
• Enrollment (Estimated): 24
• Phase: Phase 1

Contacts and Locations

• Study Contact: Name: Chao Wang, Pharm. D, BCPS, CCRP; Phone Number: 2407965552; Email: chao.wang@thewogroup.com

Study Locations

• United States
  • California
    • Los Angeles, California, United States, 90067
      • Recruiting
      • Valkyrie Clinical Trials
      • Contact: David Berz, MD, PhD, MPH
    • Whittier, California, United States, 90603
      • Recruiting
      • The Oncology Institute of Hope and Innovation
      • Contact: Pamela Miel, MD; Phone Number: 562-693-4477
      • Principal Investigator: Pamela Miel, MD
  • Maryland
    • Baltimore, Maryland, United States, 21201
      • Recruiting
      • University of Maryland, Greenebaum Comprehensive Cancer Center
      • Contact: Yixing Jiang, MD, PhD; Email: yjiang@umm.edu
      • Principal Investigator: Yixing Jiang, MD, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria Subjects must meet all the following criteria to participate this study

1. Subject with measurable disease based on RECIST 1.1.
2. Advanced, histologically or cytologically confirmed solid tumors who have progressed from current therapy or who have relapsed after prior therapy and are not candidates for potentially curative therapy.
3. Pathologically confirmed solid tumors.
4. Patients with advanced solid tumors (unresectable or metastatic) who failed standard therapy (disease progression or intolerance).
5. Capable of understanding the written informed consent, provides signed, dated, and witnessed written informed consent, and agrees to comply with the study protocol.
6. Age 18 years or older at first screening/ examination visit.
7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, measured within 72 hours of 1st treatment.
8. Adequate hematological function [absolute neutrophil count (ANC) ≥ 1.5 × 109/L], [Platelets ≥ 100 × 109/L], [Hemoglobin ≥ 9 g/dL], and [Serum albumin ≥ 2.8 g/dL].
9. Adequate renal function [calculated estimate glomerular filtration rate (eGFR) of ≥ 50mL/min] using the CKD-EPI Creatinine Equation (2021).
10. Adequate hepatic function [total bilirubin ≤ 1.5 x UNL; AST (aspartate transaminase) or ALT (alanine transaminase) ≤ 3 x UNL or ≤ 5 x UNL if due to liver involvement by tumor.
11. Negative pregnancy test for women of child-bearing potential (WOCBP) and males need to agree to use a highly effective method of contraception if not surgically sterile prior to study entry, while on drug, and for 3 months' time after the last dose. Please refer to Appendix 1 for acceptable effective contraceptive methods.
12. Subject who has predicted life expectancy of at least 12 weeks.

Exclusion Criteria Subjects meet one or more of below criteria will be excluded

1. Lactating, pregnant, or intend to be pregnant.
2. Received anti-cancer therapy or other investigational drugs within 4 weeks prior to the 1st dose of study drug.
3. Patient in use of sensitive substrates of major cytochrome P450 enzymes and transporters based on FDA Drug Development and Drug Interactions, Table of Substrates, Inhibitors, and Inducers, or strong inducers of transporter, P-gp, including apalutamide, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John's wort. Patient in use of strong inhibitors of transporters based on based on FDA Drug Development and Drug Interactions, Table of Substrates, Inhibitors, and Inducers (Appendix 2).
4. All acute toxic effect of any prior antitumor therapy resolved to Grade 1 before the start of study therapy (with the exception of alopecia [G 1 or 2 permitted], neurotoxicity [Grade ≤ 2 permitted], or selected lab parameters [Grade < 2 permitted with exceptions noted below].
5. Has evidence of another malignancy not in remission or history of such a malignancy within the last 3 years (except for treated basal or squamous cell carcinoma of the skin, or in situ cancer of the cervix). Concomitant malignancies except carcinoma in situ, basal or squamous cell skin carcinoma; low grade prostate cancer treated with prostatectomy more than 5 years ago; early-stage melanoma treated with complete surgical excision more than 5 years ago; carcinoma in situ of cervix treated with cone procedure more than 8 years ago.
6. Has symptomatic central nervous system (CNS) metastases, except where metastases are stable over a three-month period.
7. Has unstable bleeding disorder or currently under non-established course of anticoagulant therapy (except for the use of heparinized saline to maintain the patency of central venous catheters).
8. Has a medical history of symptomatic CHF (New York Heart Association [NYHA] classes II-IV) or serious cardiac arrhythmia requiring treatment.
9. Has a medical history of myocardial infarction or unstable angina within 6 months before registration.
10. Has a QTcF prolongation to > 470 ms based on a 12-lead ECG in triplicate, or other abnormalities that in the opinion of the Investigator increase the risk of participating in the study.
11. Has higher or equal to Grade 3 hypertension (≥ 160/100 mmHg) or ≤ 80/50 mmHg; has heart rate (HR) ≥ 100 beats per minute (bpm), or ≤ 45 bpm, confirmed by a repeat assessment.
12. Has evidence of electrolyte imbalance such as hypokalemia, hypocalcemia, and hypomagnesaemia of NCI-CTCAE Grade ≥ 2 (symptomatic, intervention indicated).
13. Major surgery besides tumor resection, within 4 weeks prior to screening
14. Has uncontrolled diabetes mellitus, neurologic or psychiatric condition, an ongoing systemic (including opportunistic) clinically significant infections or any other significant or unstable concurrent medical illness that may increase the risk of study participants determined by Investigator.
15. Has a known history of human immunodeficiency virus

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: WGI-0301	Drug: WGI-0301; WGI-0301 is a lipid nanoparticle preparation of Archexin® for the treatment of advanced solid tumors.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety and tolerability	Incidence and severity of treatment-related adverse events and serious adverse events	Approximately 16 months
Recommended Phase 2 Dose of WGI-0301	Based on dose-limiting toxicities, the maximal tolerated dose and all other available safety, pharmacokinetic/pharmacodynamic data as assessed by the cohort review committee	Approximately 16 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Area under the curve	Area under the plasma concentration time curve of WGI-0301	Approximately 16 months
Maximum plasma concentration	Highest observed plasma concentration of WGI-0301	Approximately 16 months
Time of maximum plasma concentration	Time to reach highest observed plasma concentration of WGI-0301	Approximately 16 months
Half-life	Plasma concentration half-life of WGI-0301	Approximately 16 months

Collaborators and Investigators

• Sponsor: Zhejiang Haichang Biotech Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): August 1, 2022
• Primary Completion (Estimated): October 15, 2024
• Study Completion (Estimated): December 31, 2024

Study Registration Dates

• First Submitted: February 8, 2022
• First Submitted That Met QC Criteria: February 23, 2022
• First Posted (Actual): March 7, 2022

Study Record Updates

• Last Update Posted (Actual): September 26, 2023
• Last Update Submitted That Met QC Criteria: September 25, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms
• Other Study ID Numbers: WGI0301-P1U

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No